Kura Oncology Inc. (KURA)
Summary
Kura Oncology: A Menin Inhibitor Launch With More Than One Way To Win
Kura Oncology is positioning ziftomenib (KOMZIFTI) as a combination backbone in AML, not just a relapsed/refractory monotherapy. KURA's robust cash position, bolstered by Kyowa Kirin payments, is expected to fund the pivotal KOMET-017 trial through the topline readout in 2028. Recent combination data show high remission rates and tolerability, supporting the platform thesis and expanding addressable AML market potential.
Kura Oncology, Inc. (KURA) Discusses Long-Term Results of Ziftomenib Combination Therapies in Newly Diagnosed and Relapsed/Refractory AML Transcript
Kura Oncology, Inc. (KURA) Discusses Long-Term Results of Ziftomenib Combination Therapies in Newly Diagnosed and Relapsed/Refractory AML Transcript
Kura Oncology, Inc. (KURA) Discusses Clinical Data and Updated Development Strategy for Darlifarnib Transcript
Kura Oncology, Inc. (KURA) Discusses Clinical Data and Updated Development Strategy for Darlifarnib Transcript
Kura Oncology Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 692 | $6,837.65 | $7,790.61 | $952.96 | 13.94% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 55,530 | $804,335.35 | $626,228.47 | -$178,106.88 | -22.14% |
| BG Bart Gancher Intech Investment Management LLC | 21,645 | $176,719.18 | $242,424 | $65,704.82 | 37.18% |
 Anthony Scaramucci SkyBridge Capital II LLC | 3.74M | $31.36M | $41.76M | $10.41M | 33.2% |
 Didric Cederholm Lion Point Capital LP | 46,000 | $407,100 | $515,200 | $108,100 | 26.55% |
Kura Oncology Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| DB Daniel Brims Lake Street | 3,646.97 | $33,333.33 | $39,624.36 | $6,291.03 | 18.87% |
Kura Oncology Inc. (KURA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Kura Oncology Inc. ever had a stock split?
Kura Oncology Inc. Profile
| Biotechnology Industry | Healthcare Sector | Troy Wilson CEO | NASDAQ (NGS) Exchange | 50127T109 CUSIP |
| US Country | 260 Employees | - Last Dividend | - Last Split | 22 Sep 2015 IPO Date |
Overview
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel medicines for the treatment of cancer. With a strategic approach to cancer therapy, Kura Oncology leverages a pipeline of small molecule product candidates aimed at distinct cancer targets. Founded in 2014, the company is pioneering advancements in oncology, seeking to address unmet medical needs within the cancer treatment landscape. Headquartered in San Diego, California, Kura Oncology stands at the forefront of cancer research, aiming to deliver innovative solutions to patients worldwide.
Products and Services
- Ziftomenib
This product candidate is an orally bioavailable small molecule inhibitor specifically designed to disrupt the interaction between menin and KMT2A. Targeting genetically defined subsets of acute leukemias, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), ziftomenib represents a promising avenue for the treatment of these challenging cancers.
- Tipifarnib
Tipifarnib is an oral farnesyl transferase inhibitor that has shown potential when used in combination with alpelisib for patients suffering from PIK3CA-dependent Head and Neck Squamous Cell Carcinoma (HNSCC). This innovative approach leverages the inhibition of farnesyl transferase to potentially overcome cancer cell growth and survival in specific patient populations.
- KO-2806
Serving as another farnesyl transferase inhibitor in Kura Oncology's arsenal, KO-2806 is currently being developed for the treatment of solid tumors. By targeting the same enzyme pathway as tipifarnib but with different properties, KO-2806 embodies the company’s commitment to diversifying its approach to cancer treatment through precision medicine.
In addition to its proprietary products, Kura Oncology has embarked on a clinical collaboration with Novartis Pharma AG. This partnership is dedicated to evaluating the combination of tipifarnib and alpelisib in a specific patient demographic with head and neck squamous cell carcinoma, highlighting the company's ongoing efforts to explore synergistic effects between different cancer therapies.
